Michael C. Skaff, through SP Manager LLC and affiliated V-Co investment vehicles, reported beneficial ownership of 19.9% of Vivos Therapeutics, Inc. common stock. The Schedule 13D, filed on Jul. 15, 2026, follows a June 30 private placement that included convertible preferred shares and warrants. The position is capped by a 19.99% ownership blocker that limits conversions and exercises.

Investor Intent

Skaff states he holds the stake for investment and plans to talk with Vivos Therapeutics’ leadership about performance, strategy, operations, and governance. He notes he "intends to engage, or has engaged, in discussions with the Issuer and its management and/or board of directors regarding the Issuer's financial performance, strategic direction, operational matters, and corporate governance practices."

On June 30, V-Co Investors 4 LLC bought 2,749,330 shares of Series A Convertible Preferred Stock and a warrant for up to 2,749,330 common shares, with the warrant immediately exercisable for five years at $0.456 per share. A strict cap applies: V-Co 4 "is prohibited from converting such Convertible Preferred Stock and exercising such Common Stock Warrants if it results in V-Co 4 or its affiliates owning in excess of 19.99%" of Vivos’ outstanding common stock.

Investor's Background

Michael C. Skaff serves as managing director of SP Manager LLC, which manages the V-CO, V-Co 2, V-Co 3, and V-Co 4 investment entities. Through these vehicles, he pursues negotiated investments that can include convertible preferred stock and stock purchase warrants. His approach emphasizes active engagement with company leadership while observing ownership limits that avoid triggering change-of-control hurdles.

Original SEC Filing: Vivos Therapeutics, Inc. [ VVOS ] - SCHEDULE 13D - Jul. 15, 2026